| http://dbpedia.org/ontology/abstract
|
Le lorlatinib est une molécule utilisée co … Le lorlatinib est une molécule utilisée comme un inhibiteur de l'ALK de troisième génération. Il est efficace dans les formes résistantes aux inhibiteurs de l'ALK de première (crizotinib) et de deuxième génération (ceritinib et alectinib). Il passe la barrière hémato-encéphalique, ce qui permet son utilisation en cas de métastases cérébrale. Dans le cancer bronchique non à petites cellules, ALK+, il permet un taux de réponse supérieur au crizotinib.n taux de réponse supérieur au crizotinib.
, ロルラチニブ (英語: Lorlatinib、PF-6463922) は、ファイザー社により開発された抗がん剤の1つである。低分子の分子標的治療薬で、とALKを阻害する。
, Lorlatinib, sold under the brand name Lorb … Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer. play a role in the development of cancer.
|
| http://dbpedia.org/ontology/alternativeName
|
Lorbrena, Lorviqua
|
| http://dbpedia.org/ontology/bioavailability
|
81
|
| http://dbpedia.org/ontology/casNumber
|
1454846-35-5
|
| http://dbpedia.org/ontology/chEBI
|
143117
|
| http://dbpedia.org/ontology/drugbank
|
DB12130
|
| http://dbpedia.org/ontology/fdaUniiCode
|
OSP71S83EU
|
| http://dbpedia.org/ontology/kegg
|
D11012
|
| http://dbpedia.org/ontology/medlinePlus
|
a619005
|
| http://dbpedia.org/ontology/pubchem
|
71731823
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Lorlatinib_Structure.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/lorlatinib +
|
| http://dbpedia.org/ontology/wikiPageID
|
52838030
|
| http://dbpedia.org/ontology/wikiPageLength
|
11721
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1102143179
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Molarity +
, http://dbpedia.org/resource/Cognitive +
, http://dbpedia.org/resource/UGT1A4 +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/Peripheral_neuropathy +
, http://dbpedia.org/resource/CYP1A2 +
, http://dbpedia.org/resource/European_Commission +
, http://dbpedia.org/resource/Grapefruit_juice +
, http://dbpedia.org/resource/PH +
, http://dbpedia.org/resource/Category:Pfizer_brands +
, http://dbpedia.org/resource/Edema +
, http://dbpedia.org/resource/Transport_protein +
, http://dbpedia.org/resource/Small_molecule +
, http://dbpedia.org/resource/In_vitro +
, http://dbpedia.org/resource/Carbamazepine +
, http://dbpedia.org/resource/Anaplastic_lymphoma_kinase +
, http://dbpedia.org/resource/Neuroblastoma +
, http://dbpedia.org/resource/CYP2B6 +
, http://dbpedia.org/resource/Progression-free_survival +
, http://dbpedia.org/resource/Kinase_inhibitor +
, http://dbpedia.org/resource/Category:Receptor_tyrosine_kinase_inhibitors +
, http://dbpedia.org/resource/CYP3A4 +
, http://dbpedia.org/resource/Enzyme_inducer +
, http://dbpedia.org/resource/Category:Fluoroarenes +
, http://dbpedia.org/resource/Bioavailability +
, http://dbpedia.org/resource/Blood-brain_barrier +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Cytochrome_P450 +
, http://dbpedia.org/resource/Non-small-cell_lung_cancer +
, http://dbpedia.org/resource/Crizotinib +
, http://dbpedia.org/resource/Plasma_protein +
, http://dbpedia.org/resource/Category:Antineoplastic_drugs +
, http://dbpedia.org/resource/Ketoconazole +
, http://dbpedia.org/resource/Pfizer +
, http://dbpedia.org/resource/Glucuronidation +
, http://dbpedia.org/resource/Hydrochloric_acid +
, http://dbpedia.org/resource/Blood_plasma +
, http://dbpedia.org/resource/Midazolam +
, http://dbpedia.org/resource/UDP-glucuronosyltransferase +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/Category:Pyridines +
, http://dbpedia.org/resource/Fatigue +
, http://dbpedia.org/resource/Committee_for_Medicinal_Products_for_Human_Use +
, http://dbpedia.org/resource/ROS1 +
, http://dbpedia.org/resource/Hypercholesterolemia +
, http://dbpedia.org/resource/Metabolite +
, http://dbpedia.org/resource/CYP2C9 +
, http://dbpedia.org/resource/Hypertriglyceridemia +
, http://dbpedia.org/resource/Category:Pyrazoles +
, http://dbpedia.org/resource/Oxidation +
, http://dbpedia.org/resource/Category:Lactams +
, http://dbpedia.org/resource/Orphan_drug_status +
, http://dbpedia.org/resource/Rifampicin +
, http://dbpedia.org/resource/St_John%27s_wort +
, http://dbpedia.org/resource/File:Lorlatinib_metabolism.svg +
, http://dbpedia.org/resource/UGT1A1 +
, http://dbpedia.org/resource/Kinase +
, http://dbpedia.org/resource/Ciclosporin +
, http://dbpedia.org/resource/CYP3A5 +
, http://dbpedia.org/resource/Liver_toxicity +
|
| http://dbpedia.org/property/atcPrefix
|
L01
|
| http://dbpedia.org/property/atcSuffix
|
ED05
|
| http://dbpedia.org/property/bioavailability
|
81.0
|
| http://dbpedia.org/property/c
|
21
|
| http://dbpedia.org/property/casNumber
|
1454846
|
| http://dbpedia.org/property/chebi
|
143117
|
| http://dbpedia.org/property/chemspiderid
|
32813339
|
| http://dbpedia.org/property/dailymedid
|
Lorlatinib
|
| http://dbpedia.org/property/drugbank
|
DB12130
|
| http://dbpedia.org/property/eliminationHalfLife
|
86400.0
|
| http://dbpedia.org/property/excretion
|
48
|
| http://dbpedia.org/property/f
|
1
|
| http://dbpedia.org/property/h
|
19
|
| http://dbpedia.org/property/iupacName
|
-7
|
| http://dbpedia.org/property/kegg
|
D11012
|
| http://dbpedia.org/property/legalAu
|
S4
|
| http://dbpedia.org/property/legalCa
|
Rx-only
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalStatus
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/medlineplus
|
a619005
|
| http://dbpedia.org/property/metabolism
|
Mainly CYP3A4 and UGT1A4
|
| http://dbpedia.org/property/n
|
6
|
| http://dbpedia.org/property/o
|
2
|
| http://dbpedia.org/property/pregnancyAu
|
D
|
| http://dbpedia.org/property/proteinBound
|
66.0
|
| http://dbpedia.org/property/pubchem
|
71731823
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/smiles
|
C[C@H]1Oc2ccc3cnnc3C#N
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
IIXWYSCJSQVBQM-LLVKDONJSA-N
|
| http://dbpedia.org/property/synonyms
|
PF-6463922
|
| http://dbpedia.org/property/tradename
|
Lorbrena, Lorviqua
|
| http://dbpedia.org/property/unii
|
OSP71S83EU
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Growth_factor_receptor_modulators +
, http://dbpedia.org/resource/Template:See +
, http://dbpedia.org/resource/Template:Targeted_cancer_therapeutic_agents +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Medcn +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Clarify +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Update_section +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Pyridines +
, http://dbpedia.org/resource/Category:Antineoplastic_drugs +
, http://dbpedia.org/resource/Category:Lactams +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/Category:Pyrazoles +
, http://dbpedia.org/resource/Category:Pfizer_brands +
, http://dbpedia.org/resource/Category:Receptor_tyrosine_kinase_inhibitors +
, http://dbpedia.org/resource/Category:Fluoroarenes +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Lorlatinib?oldid=1102143179&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Lorlatinib_Structure.svg +
, http://commons.wikimedia.org/wiki/Special:FilePath/Lorlatinib_metabolism.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Lorlatinib +
|
| owl:sameAs |
https://global.dbpedia.org/id/2Yn8K +
, http://fr.dbpedia.org/resource/Lorlatinib +
, http://yago-knowledge.org/resource/Lorlatinib +
, http://www.wikidata.org/entity/Q27285820 +
, http://ja.dbpedia.org/resource/%E3%83%AD%E3%83%AB%E3%83%A9%E3%83%81%E3%83%8B%E3%83%96 +
, http://dbpedia.org/resource/Lorlatinib +
|
| rdf:type |
http://dbpedia.org/ontology/Drug +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://www.wikidata.org/entity/Q8386 +
|
| rdfs:comment |
Lorlatinib, sold under the brand name Lorb … Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer. play a role in the development of cancer.
, ロルラチニブ (英語: Lorlatinib、PF-6463922) は、ファイザー社により開発された抗がん剤の1つである。低分子の分子標的治療薬で、とALKを阻害する。
, Le lorlatinib est une molécule utilisée co … Le lorlatinib est une molécule utilisée comme un inhibiteur de l'ALK de troisième génération. Il est efficace dans les formes résistantes aux inhibiteurs de l'ALK de première (crizotinib) et de deuxième génération (ceritinib et alectinib). Il passe la barrière hémato-encéphalique, ce qui permet son utilisation en cas de métastases cérébrale. Dans le cancer bronchique non à petites cellules, ALK+, il permet un taux de réponse supérieur au crizotinib.n taux de réponse supérieur au crizotinib.
|
| rdfs:label |
ロルラチニブ
, Lorlatinib
|
